New RRMS treatment "Vumerity" has phase 3 results shows low gastrointestinal side effects along with reduced relapse rates
multiplesclerosisnewstoday.com/vumerity-safet...Posted Jun 4, 2019, 3:20 PM UTC
33
multiplesclerosisnewstoday.com
Loading comments…